Novo Nordisk
NVO
#21
Rank
$462.34 B
Marketcap
$101.85
Share price
-3.29%
Change (1 day)
2.67%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

Earnings for Novo Nordisk (NVO)

Earnings in 2024 (TTM): $16.85 Billion USD

According to Novo Nordisk's latest financial reports the company's current earnings are $37.32 Billion USD. In 2023 the company made an earning of $15.42 Billion USD, an increase over its 2022 earnings that were of $9.78 Billion USD. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Novo Nordisk from 1996 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) $16.85 B9.23%
2023 $15.42 B57.64%
2022 $9.78 B5.35%
2021 $9.29 B12.47%
2020 $8.26 B13.07%
2019 $7.30 B-3.35%
2018 $7.55 B1.79%
2017 $7.42 B4.52%
2016 $7.10 B9.42%
2015 $6.49 B8.24%
2014 $5.99 B3.45%
2013 $5.79 B19.02%
2012 $4.87 B15.21%
2011 $4.22 B17.71%
2010 $3.59 B24.78%
2009 $2.87 B10.62%
2008 $2.60 B55.97%
2007 $1.66 B7.07%
2006 $1.55 B18.18%
2005 $1.31 B11.33%
2004 $1.18 B
2002 $0.75 B-14.39%
2001 $0.88 B-52.82%
2000 $1.86 B250%
1999 $0.53 B31.21%
1998 $0.40 B34.31%
1997 $0.30 B11.46%
1996 $0.27 B

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-$1.22 Billion-107.19%๐Ÿ‡บ๐Ÿ‡ธ USA
$10.15 B-39.77%๐Ÿ‡บ๐Ÿ‡ธ USA
-$6.88 Billion-140.82%๐Ÿ‡บ๐Ÿ‡ธ USA
$7.40 B-56.04%๐Ÿ‡ซ๐Ÿ‡ท France